The COVID-19 Therapeutics Advice & Support Group (CTAG) has been established to act as a formal advisory group to the RCP.
A subcommittee of the RCP’s Joint Speciality Committee for Infectious Disease, CTAG was established through discussion between Drugs and Therapeutics Committees, Area Prescribing Committees and specialists to provide advice and support in the management of COVID-19 whilst national guidelines evolve.
CTAG is the parent group for two key subgroups – Antivirals and Immunomodulatory - which both have a specialist membership from UK NHS providers. Each subgroup will act as a specialist panel for discussion and consensus on medicines to be used for patients with COVID-19 both within and outside of a clinical trial, whilst taking account of advice from key national stakeholders.
A wide range of organisations have come together to support and work with CTAG. As well as the RCP (lead partner), its partners include more than 20 trusts, health boards, universities and other organisations.
CTAG will provide a bridge to specific advice from relevant national health technology assessment bodies such as National Institute for Clinical Excellence (NICE), the Scottish Medicines Consortium, the All Wales Medicines Strategy Group and other national organisations.
You will find lots more information and many useful links on the CTAG website.